Role of Nanotechnology Structured Water to Achieve Controlled Blood Glucose Level in Type 2 Diabetic Patients: A Randomised Controlled Trial

• Main Authors: Ali Kamal M Sami, Mohammed Tahir Kurmanji, Kawa Amin, Ruqaya Alhassani, Jaafer Mosadek Kurmanji
• Format: Article
• Language: English
• Published: JCDR Research and Publications Private Limited 2019-11-01
• Series: Journal of Clinical and Diagnostic Research
• Subjects: diabetes mellitus; glycated hemoglobin hba1c; nanotechnology water
• Online Access: https://jcdr.net/articles/PDF/13294/41820_PD(SHU)_V-2(RV_KM)_CE[Ra1]_F(KM)_PF1(AJ_OM)_PFA(AJ_KM)_PN(SL).pdf
• ISSN: 2249-782X; 0973-709X

Introduction: Type 2 Diabetes Mellitus (DM) occurs due to insulin resistance or low insulin secretion or sometimes a combination of both. Nanotechnology structured water is a type of water that is produced using energy field modulators to change the biological, chemical and physical properties of water molecules and improve the bioavailability of this nano-water. Aim: To find out the effect of drinking nanotechnology structured water (Magnalife®) on the blood glucose levels in patients with Type 2 diabetes mellitus. Materials and Methods: This study was a randomised control trial involving Type 2 Diabetic patients (n=387) who were randomly divided into two groups. Group A (n=191) given nanotechnology structured water and Group B (n=196) with ordinary bottled water. Blood glucose level was measured as Glycated Haemoglobin (HbA1c) in the same laboratory for both groups. It was tested at baseline and at the end of the third month after drinking the water, they were given in a daily dose of 20 mL/kg body weight divided over the day. Turkey test and independent t-test were used to compare the results. Results: At the end of the study, only 352 patients were included (35 patients dropped out for different reasons). Interventional group (Group A) showed a significant difference between baseline HbA1c (8.1%±1.38) vs. HbA1c after 3 months (6.6%±0.85), (p<0.001). While there was no significant difference in pre-post HbA1c tests (7.9%±1.36) vs. (7.8%±1.16), (p=0.274) among the control group (Group B). The study revealed elevation in the percentage of patients with (HbA1c <7) in Group A from (25.1%) at baseline to (61.2%) after 3 months of intervention, while in Group B, the percentage of patients with (HbA1c <7) decreased from (27.2%) to (19.5%). Conclusion: The use of nanotechnology structured water Magnalife® in Type 2 diabetic patients is innovative way to achieve better control of blood glucose level.